Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -10.41% | -57.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.41% | -57.73% | |||
| Cost of Revenue | 104.10% | -58.32% | |||
| Gross Profit | -38.55% | -57.58% | |||
| SG&A Expenses | -71.35% | 298.40% | |||
| Depreciation & Amortization | 0.00% | 200.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -65.69% | 229.27% | |||
| Operating Income | 68.91% | -444.78% | |||
| Income Before Tax | 66.35% | -409.33% | |||
| Income Tax Expenses | 53.59% | -187.51% | |||
| Earnings from Continuing Operations | 66.46% | -380.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.46% | -380.83% | |||
| EBIT | 68.91% | -444.78% | |||
| EBITDA | 73.32% | -474.79% | |||
| EPS Basic | 68.91% | -320.22% | |||
| Normalized Basic EPS | 68.81% | -344.83% | |||
| EPS Diluted | 68.91% | -320.22% | |||
| Normalized Diluted EPS | 68.81% | -344.83% | |||
| Average Basic Shares Outstanding | 7.86% | 14.37% | |||
| Average Diluted Shares Outstanding | 7.86% | 14.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||